MIAMI BEACH, Fla., June 13, 2011 /PRNewswire/ -- Today Divine Skin Inc. (DSKX), a developer of personal-care biotechnology, announced plans to release a new oral analgesic intended to compete over the counter with the likes of Tylenol, Advil, and aspirin. The company plans to begin shipping upon final authorization by the Drug Enforcement Administration.
"Since Divine Skin focuses on underserved and niche categories, of course our pain medication will offer patients some benefits that competitors don't. The product will give better pain relief, with a safety profile similar to that of Advil," explained Daniel Khesin, chairman and CEO.
"We certainly don't expect to take significant market share away from the huge players, since consumers have been taking Tylenol and Advil for generations. Instead, we will target an audience that appreciates more advanced biotechnology. If we win just one tenth of one percent of the market — which we will — then we'll be happy," he said.
In the United States alone, manufacturers' revenue from internal non-narcotic analgesics, antipyretics, antiarthritics, and anti-inflammatories, including salicylates and acetaminophen, totaled $2.4 billion in 2009, according to an August 2010 report published by the US Census Bureau.Each patient responds differently to each type of pain and pain reliever. A few years ago, Khesin himself endured a grueling experience with chronic pain after suffering a catastrophic spinal cord injury, which put him in a wheelchair for months. During his recovery, he tried nearly all of the pain relievers then available, including some strong narcotics. That ordeal, combined with his expertise in business development and the commercialization of new biotechnologies, resulted in what he believed might become a unique over-the-counter medication. Laboratory research showed promise for the new formula, and subsequent clinical studies confirmed the drug's effectiveness.